SMCSR Offers Cardiac Patients New Drug-Eluting Stent
|
-Hospital is the first in the region to provide newly approved stent-
|
Sutter Medical Center of Santa Rosa now offers the new CYPHER Sirolimus-eluting Stent, the first drug-eluting stent to receive marketing approval from the Food and Drug Administration (FDA) for the treatment of blocked coronary arteries.
The new stent, which is approved for the treatment of previously untreated coronary artery lesions, was developed to address the problem of in-stent restenosis, or reblockage, which occurs in as many as 15-30% of patients who receive a bare metal stent. The stent is coated with the drug sirolimus, which is slowly released into the intima, or vessel lining, to prevent scar tissue growth through the openings in the stent mesh, which frequently leads to restenosis.
Results of large-scale studies involving nearly 1,400 patients worldwide show that the CYPHER Stent, manufactured by Cordis Corporation, a Johnson & Johnson company, reduces the incidence of restenosis by more than 90% over a bare metal stent.
"We are committed to bringing patients innovative new technologies that have a positive effect on patient care," explained Sutter Medical Center CEO, Mike Cohill. " We continue to provide treatment options to our patients and encourage those who have questions about the new stent to discuss their choices with their physician."
Sutter Medical Center of Santa Rosa has a long history in Sonoma County as a community based, not-for-profit hospital dating back to 1866 when the first hospital was opened. In 1996, Sutter Medical Center became an affiliate of Sutter Health. In August of 2001, the medical center debuted a state-of-the-art cardiac catheterization lab, offering a variety of interventional and diagnostic cardiovascular procedures.
|
|
|
|
